Innovation is a fundamental part of Mylan’s culture. Innovation is why we find opportunity in every challenge. It’s why you’ll find thousands of scientists, researchers and thinkers working together around the world, across oceans and time zones, to solve complex challenges and meet unmet needs.
Is it surprising that a company known for high-quality generic medicines thrives on innovation? Consider this: In 1984, we were the first generics company to earn a new drug patent. Today we design bioequivalent versions of brand name medicines and create enhance versions of medicines to differentiate our products from the pack.
To keep moving forward, we built an organisation that’s diverse, driven and unique in its ability to collaborate.
As a global company, we set out to build a research and development discipline that could leverage the strength of each individual and each local culture. Another goal was to turn a dozen time zones into an advantage.
The result: A worldwide team with a unique perspective on local and global health challenges. By working together, we turned time into a partner—when a team on one side of the planet is done for the day, a team on the other continues the work.
In other words, at Mylan, research and development never sleeps.
The way we see it, working this way makes us more responsive and drives an ever-growing portfolio that includes injectables, biologics, respiratory, oncology and neurology medicines as well as innovative treatments for HIV/AIDS.
By collaborating across continents and cultures we quickly realised that no research centre is an island. It became clear that among all the complex calculations we make, there is one simple truth: together we are greater than the sum of our parts.
Last Updated 27/02/2015